Sökning: WFRF:(Frejd Fredrik Y.) >
Human Epidermal Gro...
Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
-
- Alhuseinalkhudhur, Ali (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Lindman, Henrik (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Liss, Per, 1960- (författare)
- Uppsala universitet,Radiologi
-
visa fler...
-
Sundin, Tora (författare)
-
- Frejd, Fredrik Y. (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Hartman, Johan (författare)
- Karolinska Institutet
-
- Iyer, Victor (författare)
- Uppsala universitet,Radiologi
-
Feldwisch, Joachim (författare)
-
- Lubberink, Mark (författare)
- Uppsala universitet,Radiologi,Institutionen för immunologi, genetik och patologi
-
- Rönnlund, Caroline (författare)
- Karolinska Institutet
-
- Tolmachev, Vladimir (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Velikyan, Irina, 1966- (författare)
- Uppsala universitet,Radiologi,Translationell avbildning med PET
-
- Sörensen, Jens (författare)
- Uppsala universitet,Radiologi
-
visa färre...
-
(creator_code:org_t)
- Society of Nuclear Medicine, 2023
- 2023
- Engelska.
-
Ingår i: Journal of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505 .- 1535-5667. ; 64:9, s. 1364-1370
- Relaterad länk:
-
https://doi.org/10.2...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Imaging using the human epidermal growth factor receptor 2 (HER2)-binding tracer 68Ga-labeled ZHER2:2891-Cys-MMA-DOTA ([68Ga]Ga-ABY-025) was shown to reflect HER2 status determined by immunohistochemistry and in situ hybridization in metastatic breast cancer (MBC). This single-center open-label phase II study investigated how [68Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC. Methods: Forty patients with known positive HER2 status were included: 19 with PBC and 21 with MBC (median, 3 previous treatments). [68Ga]Ga-ABY-025 PET/CT, [18F]F-FDG PET/CT, and core-needle biopsies from targeted lesions were performed at baseline. [18F]F-FDG PET/CT was repeated after 2 cycles of therapy to calculate the directional change in tumor lesion glycolysis (Δ-TLG). The largest lesions (up to 5) were evaluated in all 3 scans per patient. SUVs from [68Ga]Ga-ABY-025 PET/CT were compared with the biopsied HER2 status and Δ-TLG by receiver operating characteristic analyses. Results: Trial biopsies were HER2-positive in 31 patients, HER2-negative in 6 patients, and borderline HER2-positive in 3 patients. The [68Ga]Ga-ABY-025 PET/CT cutoff SUVmax of 6.0 predicted a Δ-TLG lower than -25% with 86% sensitivity and 67% specificity in soft-tissue lesions (area under the curve, 0.74 [95% CI, 0.67-0.82]; P = 0.01). Compared with the HER2 status, this cutoff resulted in clinically relevant discordant findings in 12 of 40 patients. Metabolic response (Δ-TLG) was more pronounced in PBC (-71% [95% CI, -58% to -83%]; P < 0.0001) than in MBC (-27% [95% CI, -16% to -38%]; P < 0.0001), but [68Ga]Ga-ABY-025 SUVmax was similar in both with a mean SUVmax of 9.8 (95% CI, 6.3-13.3) and 13.9 (95% CI, 10.5-17.2), respectively (P = 0.10). In multivariate analysis, global Δ-TLG was positively associated with the number of previous treatments (P = 0.0004) and negatively associated with [68Ga]Ga-ABY-025 PET/CT SUVmax (P = 0.018) but not with HER2 status (P = 0.09). Conclusion: [68Ga]Ga-ABY-025 PET/CT predicted early metabolic response to HER2-targeted therapy in HER2-positive breast cancer. Metabolic response was attenuated in recurrent disease. [68Ga]Ga-ABY-025 PET/CT appears to provide an estimate of the HER2 expression required to induce tumor metabolic remission by targeted therapies and might be useful as an adjunct diagnostic tool.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Nyckelord
- HER2 positive
- PET/CT
- [68Ga]Ga-ABY-025
- affibody molecules
- breast cancer
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Alhuseinalkhudhu ...
-
Lindman, Henrik
-
Liss, Per, 1960-
-
Sundin, Tora
-
Frejd, Fredrik Y ...
-
Hartman, Johan
-
visa fler...
-
Iyer, Victor
-
Feldwisch, Joach ...
-
Lubberink, Mark
-
Rönnlund, Caroli ...
-
Tolmachev, Vladi ...
-
Velikyan, Irina, ...
-
Sörensen, Jens
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Journal of Nucle ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet